APEIRON Biologics
Apeiron Biologics is developing a potential drug candidate APN01, based on our proprietary ACE2 platform to address the growing global health threat.
Rankings by
National Ranking6th
in Austria Regional Ranking363rd
in Western Europe Global Ranking1614th
worldwide